Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Cellular Redox Balance and Tissue Injury: Full Evidence Review

Previous related pageVitamin D Supplementation and Low-Grade Inflammation in Deficient Adults: Study SummaryNext related pageVitamin D, Cellular Redox Balance and Tissue Injury: Study Summary
Study at a glance

How were vitamin D-related compounds tested for eye and kidney cell damage?

This review compares experiments on damage caused by reactive chemicals in cells. One used retinal cells, which come from the light-sensitive tissue at the back of the eye, exposed to hydrogen peroxide. Another used kidney cells exposed to high glucose and mice with diabetes. Researchers tested calcitriol, the active vitamin D hormone, or paricalcitol, a drug that activates the vitamin D receptor.

Did the tested compounds reduce signs of eye and kidney damage?

Calcitriol reduced several signs of damage in the retinal-cell model, although not every protective measurement increased clearly. Paricalcitol reduced several signs of damage from reactive chemicals and an iron-related form of cell injury in the kidney experiments. Treated mice also had better results on selected kidney-injury measurements. These are laboratory and animal findings, not demonstrated benefits in patients.

Did tests explain how the cell protection happened?

In kidney cells, reducing Nrf2, a molecule that helps control protective responses, removed or greatly weakened the measured protection. This supports its importance in that cell experiment. The retinal study did not test whether Nrf2 was required. Neither result proves that this regulator explains every change in a whole animal, and some proposed earlier steps in the proposed chain of steps in the kidney were not directly established.

Do the findings establish protection for human eyes or kidneys?

The models used small samples, and the kidney mice were male. Changes in body weight and glucose could also have contributed to their kidney results. Cell-injury measurements do not demonstrate reversal of cellular ageing. Calcitriol and paricalcitol are not equivalent to ordinary vitamin D3 supplements. These studies do not establish prevention of eye or kidney disease in people, or a personal treatment dose.

Read the full article below ↓

Vitamin D-related compounds reduced oxidative injury in experimental retinal and kidney-cell systems, but the strength of the mechanistic evidence differed between studies. Retinal-cell experiments showed coordinated changes in redox and injury markers. Kidney experiments added a test of Nrf2 dependence and animal tissue outcomes. These findings support specific experimental mechanisms; they do not establish that ordinary vitamin D supplementation prevents retinal or kidney disease in people. Read the companion Vitamin D, Cellular Redox Balance and Tissue Injury: Study Summary.

What this review compares

Tohari and colleagues investigated calcitriol in a retinal pigment epithelial cell model exposed to hydrogen peroxide. Wang and colleagues studied paricalcitol in kidney cells exposed to high glucose and in diabetic mice, with particular attention to ferroptosis-related injury. A brief complementary report by He and colleagues is considered only for its VDR: GPX4 mechanistic context.

The common physiological topic is Vitamin D and Oxidative Stress, but the models are not equivalent. Hydrogen-peroxide exposure creates an acute oxidative challenge. High-glucose cell culture and a diabetic mouse model address a different setting. Calcitriol and paricalcitol are also different experimental agents, and their results cannot be treated as direct tests of an ordinary nutritional supplement.

The review separates three questions: did redox measurements change, did cell or tissue injury change, and did an intervention on a proposed pathway show that the pathway was necessary? Answering one question does not automatically answer the others. Keeping these levels distinct is essential to a defensible tissue-protection claim.

The retinal-cell experiment

Tohari and colleagues used ARPE-19 cells, a retinal pigment epithelial cell line. Cells were challenged with hydrogen peroxide at 750 µmol/L and examined over six: or 24-hour conditions. Calcitriol was studied at 50 nmol/L. These concentrations describe laboratory exposures and are not a treatment or dosing guide.

The researchers measured several aspects of injury and redox balance. These included an MTT-based readout, reactive oxygen species, caspase-related activity, malondialdehyde, glutathione and selected antioxidant enzyme measures. Using multiple endpoints gives a broader picture than a single dye-based assay, although the endpoints are not independent clinical outcomes.

Calcitriol was associated with improved responses to the oxidative challenge across several of these measurements. The pattern included lower oxidative-injury signals and changes consistent with stronger antioxidant capacity. The study therefore supports a cellular protective response under its specified exposure conditions.

An MTT result should not be treated as a complete count of living, normally functioning retinal cells. It is an assay influenced by cellular metabolic activity. Likewise, a reactive-oxygen measurement, an apoptosis-associated readout and a lipid-peroxidation marker each capture different aspects of the response. Their convergence is useful, but it does not make them interchangeable.

NRF2 and IL-33: association versus necessity

The retinal study reported increased NRF2-related expression in the calcitriol-treated setting. NRF2 is relevant to antioxidant-response regulation, so this finding offers a plausible connection between the exposure and the redox measurements. However, the investigators did not block or remove NRF2 to test whether it was necessary for the protective response.

The paper also examined IL-33. Calcitriol altered IL-33-related expression, and recombinant IL-33 was tested for effects on selected genes. These experiments provide additional biological context, but they do not establish that IL-33 is the required intermediary through which calcitriol produced all the observed protection.

The distinction is important for Vitamin D Signalling Pathways. An exposure may change a receptor-related system, a transcriptional regulator and an injury marker at the same time. Without a perturbation that interrupts the proposed sequence, the evidence does not establish that every step is causally necessary. A coherent hypothesis remains different from a demonstrated dependency.

The study also included observations of IL-33 across mouse ages. Those observations were separate from a vitamin D intervention in ageing animals. They cannot be used to claim that calcitriol reversed age-related retinal changes in vivo. The experimental arms answer related but distinct questions.

Details that constrain the retinal conclusion

The measured GPX1 response did not show the clear increase that a broad reading of the discussion might suggest. This review therefore retains the reported null qualification rather than describing every antioxidant pathway as enhanced. An otherwise coherent pattern does not justify replacing a non-significant individual result with a positive one.

The experiments generally used small replicate numbers. Repeated measurements in one cell line do not establish how diverse human retinal tissues would respond. The model lacks many features of an intact eye, including tissue architecture, vascular influences and interactions among multiple retinal cell types.

There are also inconsistencies in the reporting of vehicle details. These do not support reconstructing a uniquely certain protocol beyond what the paper provides. They add caution to precise replication claims and reinforce the value of focusing on the observed pattern within the stated experimental setting.

The strongest conclusion is therefore a bounded one: calcitriol altered redox and injury responses in ARPE-19 cells exposed to hydrogen peroxide. The work does not establish a required NRF2 or IL-33 pathway, a clinical retinal benefit or a nutritional dose that would reproduce the effect.

Kidney injury and ferroptosis-related measurements

Wang and colleagues examined paricalcitol in a diabetic kidney-injury model and in cultured HK-2 cells exposed to high glucose. Paricalcitol is a vitamin D receptor agonist used here as an experimental compound. It should not be treated as equivalent to taking vitamin D3 as a nutritional supplement.

The mouse experiment used male db/db mice and comparison groups, with six animals per group in the reported design. Treatment was administered over ten weeks. The cell experiments compared high glucose with a normal-glucose condition and an osmotic control, and included paricalcitol and a ferroptosis inhibitor in relevant comparisons.

The osmotic control is an important design feature. High glucose changes both glucose availability and the osmotic environment. A suitable control helps distinguish effects associated with glucose exposure from effects that could arise simply because the medium contains more dissolved material. It does not remove every limitation of the cell model, but it addresses a specific alternative explanation.

Ferroptosis-related injury was assessed through a pattern of measurements, including iron, lipid-peroxidation and redox markers, relevant proteins and mitochondrial appearance. A single marker would be insufficient to identify a whole cell-death process confidently. The study’s use of several complementary readouts strengthens its experimental argument.

What changed with paricalcitol?

In the reported kidney-cell and animal experiments, paricalcitol was associated with lower oxidative and lipid-peroxidation signals and changes in iron handling. Glutathione and several protective proteins, including GPX4 and SLC7A11, moved in a direction consistent with reduced ferroptosis-related stress. Other examined proteins included FTH1, FSP1 and TFR1.

The directions of FTH1 and TFR1 in parts of the discussion do not align cleanly with the reported results. The interpretation here follows the experimental results and figures rather than repeating the contradictory wording. This is important because reversing iron-storage and iron-uptake directions would change the proposed mechanism.

Mitochondrial structural appearances also improved in the treated experimental setting. This is relevant to Vitamin D and Mitochondrial Function, but morphology is not a complete measure of mitochondrial performance. The images should not be restated as proof that every aspect of cellular energy production was restored.

In the mice, treatment was associated with improvements in urinary albumin-to-creatinine ratio, histological injury and kidney-injury marker measurements. These outcomes extend the evidence beyond cultured cells. They support a tissue-level protective association in the animal model, while remaining distinct from clinical kidney outcomes in humans.

Nrf2 knockdown strengthened the mechanism

A particularly useful part of Wang’s study was the use of Nrf2-targeting small interfering RNA in the cell experiments. When Nrf2 was reduced, the reported protective redox and iron-related responses to paricalcitol were lost or markedly attenuated. This directly tests pathway dependence rather than merely observing that Nrf2 expression rose alongside protection.

The investigators also used trigonelline as a pharmacological intervention in the pathway analysis. That result provides a complementary line of evidence, although a pharmacological inhibitor is not identical to a genetic perturbation and may have effects beyond a single target. The convergence of approaches is more informative than either measurement alone.

The appropriate conclusion is that Nrf2 was required for the measured protective response in the tested cell setting. It is not that Nrf2 was proved necessary for every animal outcome. The study did not use an animal Nrf2 knockout to establish that broader claim, and the scope of the dependency test should remain attached to the experiment in which it was performed.

Likewise, evidence involving an Nrf2/HO-1-associated pathway does not establish that HO-1 itself was uniquely necessary unless its role was specifically disrupted. Naming a pathway should not conceal differences in how directly each component was tested.

Receptor binding was not fully demonstrated in this paper

Wang and colleagues included a prediction concerning VDR interaction with the NFE2L2 regulatory region and examined cellular localisation. A predicted binding site is not direct evidence of binding, and colocalisation does not prove that a receptor occupies a particular promoter or activates it through that site.

The study did not provide VDR knockout evidence establishing the complete proposed receptor-to-Nrf2 sequence. Its strongest causal contribution is the Nrf2-dependency experiment in cells. The upstream VDR-binding step remains less directly established by this paper and should not be given the same evidential status.

For brief complementary context, He and colleagues reported VDR loss/gain and GPX4 promoter-related experiments in a renal ferroptosis model, including binding-focused assays. These findings support a more directly tested VDR: GPX4 mechanism in that separate programme. They do not establish that nutritional vitamin D prevents human kidney disease or that Wang’s proposed VDR: Nrf2 binding step was directly demonstrated.

Why the animal protection is not a complete clinical mechanism

Paricalcitol also changed body weight and glucose-related measures in the diabetic mice. These changes complicate attribution of improved kidney outcomes solely to a direct renal redox mechanism. If the metabolic environment changes alongside the kidney measurements, part of the organ response could arise through that broader change.

The cultured-cell experiments help investigate a direct cellular response under controlled conditions. They do not prove that the same mechanism accounts for the entire animal effect. Combining cell and animal results strengthens plausibility, but it does not remove the need to test mediation and competing pathways in the intact organism.

The small, male-only animal groups and disease-specific model also restrict generalisation. A ten-week result in db/db mice is not evidence of long-term preservation of kidney function in diverse human patients. Differences in drug exposure, disease course and background treatment remain unresolved by this study.

Links to inflammation and cellular ageing

Oxidative stress is closely related to the processes discussed in Vitamin D and Inflammatory Signalling, but this review does not establish that every protective redox response worked by suppressing inflammatory signalling. The studies measured particular pathways and outcomes. A broader inflammatory mechanism should not be inserted where it was not causally tested.

Similarly, these injury models do not demonstrate reversal of cellular senescence, the distinct process discussed in Vitamin D and Cellular Senescence. Acute oxidative injury, ferroptosis-related stress and cellular senescence are different processes. A reduction in injury markers cannot be renamed an anti-senescence effect without measuring the relevant senescence features and their persistence.

The distinction between experimental exposure and human status is reflected in Vitamin D Status vs Vitamin D Effect. Directly adding calcitriol or paricalcitol to a cell system tests responsiveness under controlled conditions. It does not determine how a person’s circulating 25-hydroxyvitamin D concentration relates to local tissue exposure or clinical benefit.

These model and endpoint differences also explain part of Why Vitamin D Results Differ. Results can appear inconsistent when studies ask different questions with different agents and tissues. The remedy is to specify the tested claim, rather than average all findings into a broad assertion that vitamin D is protective everywhere.

Conclusion

The retinal study supports coordinated redox and injury changes with calcitriol in a cell model, while leaving NRF2 and IL-33 necessity unproven. The kidney study adds Nrf2-dependency evidence in cells and protective tissue outcomes in diabetic mice, with metabolic confounding and upstream receptor-mechanism limits still present.

Together, these findings support specific experimental routes through which vitamin D-related signalling can influence oxidative injury. They do not establish clinical tissue protection from ordinary supplementation, an anti-ageing effect or a personal treatment regimen. The strength of each claim depends on the model, the measured outcome and how directly the proposed mechanism was tested.

This page is an original Vitamin D3 For Life explanation and critical appraisal of the research cited below.

Primary source and publication details

Related reading

Original sources

Source

Vitamin D Attenuates Oxidative Damage and Inflammation in Retinal Pigment Epithelial Cells

In the current study, we investigated the impact of VITD on H2O2-induced oxidative stress and inflammation in human RPE cells.

Publication details

Vitamin D Attenuates Oxidative Damage and Inflammation in Retinal Pigment Epithelial Cells. Ali Mohammad Tohari, Reem Hasaballah Alhasani, Lincoln Biswas, Sarita Rani Patnaik, James Reilly, Zhihong Zeng, Xinhua Shu. Antioxidants; 2019; 8; 9; 341. DOI: 10.3390/antiox8090341. CC BY. This page provides an original explanatory appraisal; no source figures are reproduced.

Read more →
Source

VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf 2/HO‐1 Signaling Pathway in Diabetic Nephropathy

VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf 2/HO‐1 Signaling Pathway in Diabetic Nephropathy.

Publication details

VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf 2/HO‐1 Signaling Pathway in Diabetic Nephropathy. Hui Wang, Xiaoyue Yu, Dongwei Liu, Yingjin Qiao, Jinling Huo, Shaokang Pan, Lijuan Zhou, Rui Wang, Qi Feng, Zhangsuo Liu. Advanced Science; 2024; 11; 10; 2305563. DOI: 10.1002/advs.202305563. CC BY. This page provides an original explanatory appraisal; no source figures are reproduced.

Read more →
Source

PRPF19 mediates the proteasomal degradation of VDR to exacerbate ferroptosis in diabetic nephropathy

PRPF19 mediates the proteasomal degradation of VDR to exacerbate ferroptosis in diabetic nephropathy.

Publication details

PRPF19 mediates the proteasomal degradation of VDR to exacerbate ferroptosis in diabetic nephropathy. Qiongyao He, Wu He, Yanlin Ren, Wenbin Wu, Hui Dong, Gang Yuan, Huihui Ren, Xinwei Wang, Fuer Lu, Dingkun Wang. Cell Communication and Signaling : CCS; 2025; 23; 242. DOI: 10.1186/s12964-025-02253-5. CC BY-NC-ND; linked here for brief factual context only.

Read more →